Contrast-Associated Acute Kidney Injury: Risk Assessment and Prevention

Definition and terminology

Contrast-associated acute kidney injury is an acute deterioration in renal function occurring after exposure to iodinated contrast media, particularly during cardiovascular angiography, computed tomography, or percutaneous coronary intervention. The preferred terminology is contrast-associated AKI when temporal association is present; contrast-induced AKI should be reserved for the smaller subgroup in which iodinated contrast is considered causally responsible.

This distinction is important because AKI after a contrast study frequently occurs in patients with several simultaneous renal insults. Infection, hypovolaemia, cardiac dysfunction, haemodynamic instability, anaemia and other nephrotoxic exposures may contribute to tubular injury, making attribution to contrast alone difficult.

In patients with normal renal function, the occurrence of contrast-induced AKI is negligible or very low. Risk rises substantially with chronic kidney disease, particularly diabetic kidney disease and advanced CKD. The clinical course is often more rapidly reversible than that of other forms of acute tubular necrosis, although the complication remains associated with post-procedural morbidity and mortality.

Pathophysiology

The precise mechanism of contrast-induced AKI is incompletely defined. In many cases, the renal injury probably represents acute tubular necrosis arising from the combined effects of contrast exposure and other ischaemic or nephrotoxic stresses.

The kidney is particularly vulnerable to toxic injury because of its high blood flow and the concentration of filtered substances along the nephron as water is reabsorbed. Nephrotoxic injury may involve the tubules, interstitium, renal vasculature or collecting system. With iodinated contrast, the observed renal dysfunction may therefore reflect a combination of:

• direct tubular toxicity;

• renal haemodynamic disturbance and ischaemia;

• pre-existing or concurrent hypovolaemia;

• cardiac dysfunction or haemodynamic instability; and

• additional nephrotoxic exposures.

The typical biochemical pattern is a rise in serum creatinine beginning 24–48 hours after exposure, with a peak at approximately 3–5 days and resolution within about 1 week in the usual course. Severe AKI requiring dialysis is uncommon except in the presence of substantial pre-existing CKD, particularly when congestive heart failure or other causes of ischaemic AKI coexist.

Risk assessment

Patient-related risk factors

The principal determinant of risk is baseline renal function. The risk is increased by:

• CKD, especially advanced CKD;

• diabetic kidney disease;

• older age;

• diabetes mellitus;

• hypovolaemia or extracellular fluid depletion;

• congestive heart failure or other cardiac dysfunction;

• haemodynamic instability;

• anaemia;

• multiple myeloma or other renal disease;

• hepatic disease;

• concurrent nephrotoxic drugs, including NSAIDs; and

• repeated or high-volume contrast exposure.

Patients with multiple myeloma and renal disease are particularly susceptible. The risk is also greater when several predisposing factors coexist, rather than being determined by contrast exposure in isolation.

Estimated glomerular filtration rate

Reported estimates include a rate of approximately 0–2% in patients with an eGFR of 30–44 mL/min/1.73 m2 and up to 17% when eGFR is below 30 mL/min/1.73 m2. In patients with relatively normal renal function, defined in the source material as eGFR above 60 mL/min, the risk is low.

In patients undergoing percutaneous coronary intervention, even mild baseline renal dysfunction is associated with worse outcomes. The risk of death at 1 year is increased in comparison with patients with preserved renal function, although the association may not be causal. Renal dysfunction after PCI may reflect contrast-associated injury, haemodynamic instability, cholesterol embolisation, or a combination of these mechanisms.

Contrast volume

Contrast dose is a modifiable determinant of risk. In CKD, guidelines recommend assessing the ratio of contrast volume in millilitres to eGFR and avoiding a ratio above 3.7. For ultralow-contrast angiography, contrast should be restricted so that the contrast-volume-to-eGFR ratio is below 1; a ratio above 1 has been associated with a marked increase in contrast-induced AKI in advanced CKD.

Clinical presentation

Contrast-associated AKI is generally identified by a post-exposure rise in serum creatinine rather than by a distinctive symptom complex. The usual onset is delayed, with creatinine increasing within 24–48 hours, reaching its maximum at 3–5 days and recovering within approximately 1 week.

More severe cases may occur in patients with advanced CKD and concomitant congestive heart failure or other causes of renal ischaemia. Dialysis-requiring AKI is uncommon in uncomplicated cases. The source material does not describe a specific physical examination syndrome unique to contrast-associated AKI.

Evaluation and physical examination

Assessment should establish:

• baseline renal function;

• the presence and severity of CKD;

• volume status and the possibility of hypovolaemia;

• cardiac function and haemodynamic stability;

• diabetes, anaemia, hepatic disease and multiple myeloma;

• exposure to NSAIDs or other nephrotoxins; and

• the anticipated contrast volume and whether a lower-contrast or contrast-free strategy is feasible.

Clinical evaluation should also consider alternative or additional causes of post-procedural AKI, including infection, haemodynamic compromise, cardiac dysfunction, ischaemic tubular injury and cholesterol embolisation syndrome. Catheter manipulation in an atherosclerotic ascending or descending aorta may release cholesterol crystals and produce renal dysfunction.

Routine peri-procedural renal assessment is especially important in patients with recognized risk factors. In patients undergoing intermediate- or high-risk non-cardiac surgery, risk factors that warrant pre-operative screening include age above 65 years, body mass index above 30 kg/m2, diabetes, hypertension, hyperlipidaemia, cardiovascular disease and smoking. Screening consists of serum creatinine and GFR measurement. If available, cystatin C should be considered when eGFR is impaired, particularly in the range below 45–59 mL/min/1.73 m2, to confirm kidney disease.

Diagnostics and laboratory findings

Serum creatinine and eGFR

Serum creatinine should be measured before contrast exposure in patients at risk and monitored after the procedure when clinically indicated. The characteristic pattern is:

In most patients, renal function returns to baseline within 7–10 days and does not progress to chronic renal failure. The course may be more severe when advanced CKD, heart failure or other causes of AKI are present.

The diagnostic evaluation should not assume that every post-contrast creatinine rise is contrast-induced. The clinical context should be reviewed for hypovolaemia, infection, haemodynamic instability, cardiac dysfunction, other nephrotoxins and cholesterol embolisation.

Other laboratory findings

The source material does not provide a specific biomarker panel for contrast-associated AKI beyond serum creatinine and estimated GFR. It also does not establish a role for a particular novel renal biomarker.

Contrast agents and renal safety

Iodinated contrast media

Adverse reactions to iodinated contrast are well recognized. Nonionic formulations have an overall reaction rate of approximately 0.4–3%, with higher rates reported for ionic formulations. Most reactions are mild and self-limited.

The risk of contrast-induced nephropathy is low in patients with eGFR above 60 mL/min. It increases when eGFR falls below 60 mL/min, particularly in older patients with diabetes, and is highest in advanced CKD and in those with multiple additional risk factors.

Gadolinium-based contrast agents

Gadolinium-based contrast agents improve CMR tissue characterization and delineation of cardiac or vascular structures. Mild reactions, such as itching or erythema, occur in approximately 1% of patients, whereas severe or anaphylactic reactions are very rare.

Older group I linear agents have been associated with nephrogenic systemic fibrosis, a potentially severe fibrosing inflammatory disorder that can involve tissues and internal organs and may be fatal. Risk factors include:

• high-dose group I agent exposure;

• eGFR below 30 mL/min/1.73 m2;

• haemodialysis;

• eGFR below 15 mL/min/1.73 m2;

• acute renal deterioration; and

• concurrent pro-inflammatory or systemic illness.

Group II macrocyclic agents have a markedly better safety profile in chronic kidney dysfunction and are now the preferred agents in most MRI centres. The American College of Radiology considers group II agents safe in severe renal dysfunction and in patients receiving dialysis. With group II agents, weight-based dosing and contemporary practice have been associated with a near-zero incidence of nephrogenic systemic fibrosis in the past decade. For a clinically indicated MRI using a group II agent, routine pre-test eGFR screening is no longer recommended in the source material.

Echocardiographic contrast

Agitated saline is routinely used to evaluate intracardiac shunts. Because the bubbles are too large to pass through the pulmonary circulation, their appearance in the left-sided cardiac chambers indicates a shunt, although the precise location may not always be clear.

FDA-approved echocardiographic contrast agents are used to opacify the left-sided chambers and improve left ventricular endocardial border definition when the echocardiographic study is suboptimal. These agents consist of albumin- or lipid-based microspheres containing inert gases, usually perfluorocarbons. They are considered extremely safe, although exceptionally rare allergic and neurological events have been reported.

Prevention

General principles

Prevention is based on identifying high-risk patients, minimizing contrast exposure, maintaining appropriate intravascular volume and avoiding additional renal insults. The principal strategies are:

• assess baseline renal function;

• identify CKD and other risk factors;

• use the smallest feasible contrast volume;

• use low-osmolar or iso-osmolar iodinated contrast media when appropriate;

• provide isotonic intravenous hydration in selected high-risk patients;

• avoid or withdraw avoidable nephrotoxins where clinically feasible; and

• monitor renal function after exposure in patients at increased risk.

Hydration

Hydration is a central preventive strategy, but its intensity and timing must be individualized, particularly in patients with heart failure. In patients with eGFR below 30 mL/min/1.73 m2 undergoing angiography or intervention, pre- and post-procedure intravenous hydration with normal saline should be considered. It should also be considered in high-risk patients with eGFR between 30 and 44 mL/min/1.73 m2.

For patients with CKD undergoing coronary angiography or revascularization, adequate hydration with isotonic saline from 12 hours before until 24 hours after contrast exposure is described as essential for prevention. In some interventional settings, hydration may be guided by left ventricular end-diastolic pressure.

Because excess fluid may be hazardous in cardiac dysfunction, hydration should take account of clinical circumstances, cardiac filling pressures and the risk of congestion.

Contrast minimization

Contrast volume should be deliberately limited. In advanced CKD, ultralow-contrast angiography aims for a contrast-volume-to-eGFR ratio below 1. When PCI is required, a staged zero-contrast strategy may be used. The initial ultralow-contrast angiogram serves as an anatomical roadmap, while intravascular imaging guides stent deployment across the target lesion. Staging allows an interval for renal recovery between procedures.

Early data support ultralow-contrast and zero-contrast techniques for renal outcomes, although larger randomized studies are required for confirmation.

Choice of contrast formulation

For patients with renal disease requiring peri-operative contrast-enhanced radiography, guideline recommendations support consideration of:

• balanced hydration with intravenous isotonic fluids;

• minimal contrast volume; and

• low-osmolar or iso-osmolar contrast media.

Guideline-based recommendations

The recommendations supported by the source material are summarized below.

In ACS with CKD, observational and registry data indicate better outcomes with early revascularization than with medical therapy alone, although the source material emphasizes that randomized evidence is limited. Coronary angiography should therefore be considered when clinically appropriate, balancing the expected benefit of revascularization against bleeding and contrast-associated renal risks.

When multivessel coronary disease is present, CABG is preferred over PCI in patients with acceptable surgical risk and life expectancy exceeding 1 year. PCI is recommended when surgical risk is high or life expectancy is shorter. In patients with CKD undergoing PCI, newer-generation drug-eluting stents are preferred over bare-metal stents.

Management of established contrast-associated AKI

Established contrast-associated AKI is generally managed by recognizing and correcting reversible contributors while monitoring renal function. The source material does not specify a dedicated pharmacological treatment or a medication regimen for established disease.

Management should include assessment for:

• persistent hypovolaemia;

• haemodynamic instability;

• congestive heart failure;

• infection;

• ongoing exposure to nephrotoxins;

• cholesterol embolisation; and

• other causes of acute tubular injury.

Renal function generally recovers within approximately 7–10 days in uncomplicated cases. Dialysis-requiring AKI is uncommon unless substantial pre-existing CKD or additional major insults are present. The source material does not provide specific dialysis initiation criteria for contrast-associated AKI.

Prognosis and follow-up

The prognosis is usually favourable when baseline renal function is preserved and no major concurrent renal insult exists. In many cases, the creatinine rise resolves within about 1 week, with return toward baseline within 7–10 days and no progression to chronic renal failure.

Prognosis is worse with:

• advanced CKD;

• diabetes-related kidney disease;

• congestive heart failure;

• haemodynamic instability;

• multiple nephrotoxic exposures;

• severe anaemia; and

• dialysis-requiring AKI.

Renal dysfunction is also an important marker of overall cardiovascular risk. Patients with CKD and ACS have higher rates of recurrent ischaemic events, post-PCI ischaemic complications, stent thrombosis, bleeding and treatment-related complications. In PCI populations, renal dysfunction is associated with increased mortality at 1 year, and the risk rises with the severity of baseline impairment.

Follow-up should include reassessment of renal function after contrast exposure in patients at risk, with particular attention to the expected 24–48-hour onset and 3–5-day peak in serum creatinine. Persistent or progressive dysfunction should prompt evaluation for alternative or additional causes of AKI rather than being attributed automatically to contrast.